

The information in the press release is intended for investors.

Isofol's Board of Directors appoints Roger Tell as acting CEO of the company

Gothenburg, Sweden, June 22, 2023 – Isofol Medical AB (publ) announces today that its Board of Directors has decided to appoint Roger Tell as acting CEO for the company, effective immediately.

Dr. Roger Tell (b. 1965) has been active in Isofol since 2019 and is today responsible for medical and scientific issues. He first held a position as Senior Vice President of Clinical Development and Chief Scientific Officer, thereafter, moving on to a role as Chief Medical Officer. He joined Isofol from Aprea Therapeutics, where he was Vice President of Clinical Development. Prior to Aprea, he was an International Clinical Project Director at Servier in Suresnes, France. He has an extensive experience as an oncologist as well as an advisor to a number of biopharma companies, including Eli Lilly, Astra Zeneca and Merck Serono. Dr. Tell holds a medical degree and a doctorate in experimental oncology from the Karolinska Institutet in Sweden, and he completed his residency in oncology at the Karolinska University Hospital.

"With Roger's solid background and thorough knowledge of the company, it feels natural that he is now taking the role of acting CEO. His medical experience as an oncologist also weighs heavily at the stage Isofol is right now. We look forward to Roger, together with the rest of the Isofol team, completing the stepwise strategy that the company initiated in March," says Mats Franzén, Chairman of the Board of Isofol Medical AB (publ).

Roger Tell succeeds Thomas Andersson, who informed the board on 21 June that he was leaving his position as CEO.

For more information, please contact

Isofol Medical AB (publ)

Mats Franzén, chairman of the board

E-post: mats@efficere.se

This information is information that Isofol Medical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 16:35 CEST on June 22, 2023.

About Isofol Medical AB (publ)

Isofol Medical AB (publ) is developing the drug candidate arfolitixorin with the aim of increasing the efficacy of current standard treatments for colorectal cancer and certain other tumor diseases. A Phase III study of arfolitixorin has been completed and the company is now evaluating opportunities to advance the drug candidate toward a marketing authorization application by conducting additional studies and entering potential partnerships. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.

www.isofolmedical.com